Publication Name	World Journal of Gastroenterology
Manuscript ID	104429
Country	China

Received	2024-12-19 15:35
Peer-Review Started	2024-12-20 01:35
To Make the First Decision
Return for Revision	2025-01-10 01:28
Revised	2025-01-13 10:06
Second Decision	2025-01-24 02:36
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-01-24 06:02
Articles in Press	2025-01-24 06:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-02-17 07:27
Publish the Manuscript Online	2025-02-26 04:21

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy
Manuscript Source	Unsolicited Manuscript
All Author List	Fei-Yu Zhao, Xiao-Ming Zhang and Nian-Song Qian
ORCID	Author(s) ORCID Number Fei-Yu Zhao http://orcid.org/0009-0001-4466-5018 Xiao-Ming Zhang http://orcid.org/0009-0009-0747-9820 Nian-Song Qian http://orcid.org/0000-0002-3297-4294
Funding Agency and Grant Number
Corresponding Author	Nian-Song Qian, Chief Physician, MD, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, No. 28 Fuxing Road, Beijing 100853, China. qianniansong1@163.com
Key Words	Hepatocellular carcinoma; Bevacizumab; Lenvatinib; Sintilimab; Interventional treatment
Core Tip	Interventional therapy combined with immunotherapy and targeted therapy can significantly prolong the survival of intermediate and advanced hepatocellular carcinoma, but there are very few comparative studies studying the combination of different molecular targeted drugs, different immunotherapeutic drugs, and interventional therapy. Han et al studied the efficacy of lenvatinib or bevacizumab combined with sintilimab and interventional therapy, which can help clarify the efficacy of the combination of different drugs, providing a basis for clinicians to choose the correct treatment strategy for intermediate and advanced hepatocellular carcinoma.
Publish Date	2025-02-26 04:21
Citation	<p>Zhao FY, Zhang XM, Qian NS. Two treatment methods for hepatocellular carcinoma: Lenvatinib or bevacizumab combined with sintilimab and interventional therapy. <i>World J Gastroenterol</i> 2025; 31(10): 104429</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i10/104429.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i10.104429

Full Article (PDF)	WJG-31-104429-with-cover.pdf
Manuscript File	104429_Auto_Edited_070842.docx
Answering Reviewers	104429-answering-reviewers.pdf
Audio Core Tip	104429-audio.mp3
Conflict-of-Interest Disclosure Form	104429-conflict-of-interest-statement.pdf
Copyright License Agreement	104429-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	104429-non-native-speakers.pdf
Peer-review Report	104429-peer-reviews.pdf
Scientific Misconduct Check	104429-scientific-misconduct-check.png
Scientific Editor Work List	104429-scientific-editor-work-list.pdf
CrossCheck Report	104429-crosscheck-report.pdf